Literature DB >> 29134378

Organ Preservation in Rectal Cancer After Chemoradiation: Should We Extend the Observation Period in Patients with a Clinical Near-Complete Response?

Britt J P Hupkens1,2,3,4, Monique Maas5, Milou H Martens6, Marit E van der Sande7, Doenja M J Lambregts4, Stéphanie O Breukink1, Jarno Melenhorst1, Janneke B Houwers3, Christiaan Hoff8, Meindert N Sosef6, Jeroen W A Leijtens9, Maaike Berbee10, Regina G H Beets-Tan2,4, Geerard L Beets2,7.   

Abstract

BACKGROUND: To assess whether extending the observation period in patients with a near clinical complete response (near cCR) after chemoradiation (CRT) leads to an impaired oncological outcome.
METHODS: Patients who had a clinical complete response (cCR) 8-10 weeks after CRT restaging with magnetic resonance imaging and endoscopy were offered a watch-and-wait strategy (W&W1), while patients with a near cCR were offered to undergo local excision or a second restaging 6-12 weeks later. Patients who achieved a cCR at the second restaging were also offered a watch-and-wait strategy (W&W2).
RESULTS: Overall, 102 patients with a cCR at the first restaging immediately entered the W&W1, while the remaining 68 patients had a near cCR: 19 patients underwent transanal endoscopic microsurgery and 49 patients opted for a second restaging. Additionally, 44/49 (90%) patients showed a cCR at the second restaging and entered the W&W2. Patients in the W&W1 group had a 2-year local regrowth-free rate (LRFR) of 84% and 2-year overall survival (OS) of 99%, while patients in the W&W2 group had a 2-year LRFR of 73% and OS of 98% (p > 0.05). Multivariable Cox regression analyses showed that late inclusion was not a significant predictive factor for higher risk of LR or lower non-regrowth disease-free survival.
CONCLUSIONS: Overall, 90% of patients with a near cCR 8-10 weeks after CRT will proceed to a cCR 6-12 weeks later; therefore, it seems logical to extend the observation period rather than to proceed to surgery. Although there is a non-significant increase in local regrowth rate in these patients, it does not seem to impact the oncological outcome.

Entities:  

Mesh:

Year:  2017        PMID: 29134378     DOI: 10.1245/s10434-017-6213-8

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  23 in total

Review 1.  'Watch and wait' in rectal cancer: summary of the current evidence.

Authors:  Jason On; Emad H Aly
Journal:  Int J Colorectal Dis       Date:  2018-07-05       Impact factor: 2.571

Review 2.  Watchful Waiting after Radiochemotherapy in Rectal Cancer: When Is It Feasible?

Authors:  Cihan Gani; Andreas Kirschniak; Daniel Zips
Journal:  Visc Med       Date:  2019-03-27

3.  Predicting the tumor response to chemoradiotherapy for rectal cancer: Model development and external validation using MRI radiomics.

Authors:  Philippe Bulens; Alice Couwenberg; Martijn Intven; Annelies Debucquoy; Vincent Vandecaveye; Eric Van Cutsem; André D'Hoore; Albert Wolthuis; Pritam Mukherjee; Olivier Gevaert; Karin Haustermans
Journal:  Radiother Oncol       Date:  2019-08-17       Impact factor: 6.280

4.  Role of Local Excision for Suspected Regrowth in a Watch and Wait Strategy for Rectal Cancer.

Authors:  Barbara M Geubels; Vincent M Meyer; Henderik L van Westreenen; Geerard L Beets; Brechtje A Grotenhuis
Journal:  Cancers (Basel)       Date:  2022-06-23       Impact factor: 6.575

5.  Clinical and radiomics prediction of complete response in rectal cancer pre-chemoradiotherapy.

Authors:  Peter Mbanu; Mark P Saunders; Hitesh Mistry; Joe Mercer; Lee Malcomson; Saif Yousif; Gareth Price; Rohit Kochhar; Andrew G Renehan; Marcel van Herk; Eliana Vasquez Osorio
Journal:  Phys Imaging Radiat Oncol       Date:  2022-06-28

Review 6.  Endoscopic and MRI response evaluation following neoadjuvant treatment for rectal cancer: a pictorial review with matched MRI, endoscopic, and pathologic examples.

Authors:  Seth I Felder; Sebastian Feuerlein; Arthur Parsee; Iman Imanirad; Julian Sanchez; Sophie Dessureault; Richard Kim; Sarah Hoffe; Jessica Frakes; James Costello
Journal:  Abdom Radiol (NY)       Date:  2020-10-28

7.  Watch and Wait Approach After Neoadjuvant Chemoradiotherapy in Rectal Cancer: Initial Experience in the Indian subcontinent.

Authors:  Reena Engineer; Avanish Saklani; Ashwin D'souza; Supreeta Arya; Suman Kumar; Vikas Ostwal; Anant Ramaswamy; Supriya Chopra; Prachi Patil
Journal:  Indian J Surg Oncol       Date:  2021-09-09

8.  Adoption of Organ Preservation and Surgeon Variability for Patients with Rectal Cancer Does Not Correlate with Worse Survival.

Authors:  Jin K Kim; Hannah Thompson; Rosa M Jimenez-Rodriguez; Fan Wu; Francisco Sanchez-Vega; Garrett M Nash; Jose G Guillem; Philip B Paty; Iris H Wei; Emmanouil P Pappou; Maria Widmar; Martin R Weiser; J Joshua Smith; Julio Garcia-Aguilar
Journal:  Ann Surg Oncol       Date:  2021-10-03       Impact factor: 5.344

9.  Does restaging MRI radiomics analysis improve pathological complete response prediction in rectal cancer patients? A prognostic model development.

Authors:  Giuditta Chiloiro; Davide Cusumano; Paola de Franco; Jacopo Lenkowicz; Luca Boldrini; Davide Carano; Brunella Barbaro; Barbara Corvari; Nicola Dinapoli; Martina Giraffa; Elisa Meldolesi; Riccardo Manfredi; Vincenzo Valentini; Maria Antonietta Gambacorta
Journal:  Radiol Med       Date:  2021-11-01       Impact factor: 3.469

Review 10.  Recent advances of neoadjuvant chemoradiotherapy in rectal cancer: Future treatment perspectives.

Authors:  Kimihiro Yamashita; Takeru Matsuda; Hiroshi Hasegawa; Junko Mukohyama; Akira Arimoto; Tomoko Tanaka; Masashi Yamamoto; Yoshiko Matsuda; Shingo Kanaji; Tetsu Nakamura; Yasuo Sumi; Satoshi Suzuki; Yoshihiro Kakeji
Journal:  Ann Gastroenterol Surg       Date:  2018-10-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.